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Patterns of Adherence to Oral Hypoglycemic Agents and Glucose Control
among Primary Care Patients with Type 2 Diabetes
Abstract
Researchers sought to examine whether there are patterns of oral hypoglycemic-agent adherence among
primary-care patients with type 2 diabetes that are related to patient characteristics and clinical outcomes.
Longitudinal analysis via growth curve mixture modeling was carried out to classify 180 patients who
participated in an adherence intervention according to patterns of adherence to oral hypoglycemic agents
across 12 weeks. Three patterns of change in adherence were identified: adherent, increasing adherence, and
nonadherent. Global cognition and intervention condition were associated with pattern of change in
adherence (p < .05). Patients with an increasing adherence pattern were more likely to have an Hemoglobin
A1c) < 7%; adjusted odds ratio = 14.52, 95% CI (2.54, 82.99) at 12 weeks, in comparison with patients with
the nonadherent pattern. Identification of patients with type 2 diabetes at risk of nonadherence is important
for clinical prognosis and the development and delivery of interventions.
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Abstract
We sought to examine whether there are patterns of oral hypoglycemic agent adherence among 
primary care patients with type 2 diabetes that are related to patient characteristics and clinical 
outcomes. Longitudinal analysis via growth curve mixture modeling was carried out to classify 
180 patients who participated in an adherence intervention according to patterns of adherence to 
oral hypoglycemic agents across 12 weeks. Three patterns of change in adherence were identified: 
adherent, increasing adherence, and nonadherent. Global cognition and intervention condition 
were associated with pattern of change in adherence (p<0.05). Patients with an increasing 
adherence pattern were more likely to have an Hemoglobin A1c (HbA1c) < 7% (adjusted odds ratio 
= 14.52, 95% CI [2.54, 82.99]) at 12 weeks in comparison with patients with the nonadherent 
pattern. Identification of patients with type 2 diabetes at risk of nonadherence is important for 
clinical prognosis and the development and delivery of interventions.
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Achieving optimal glycemic control is a cornerstone in reducing risk for micro-vascular and 
macro-vascular complications in type 2 diabetes.1 Despite the development of effective 
diabetes therapies and interventions to prevent both macrovascular and microvascular 
complications and adverse events, diabetes control remains suboptimal.2-5 Oral 
hypoglycemic adherence is a critical component of diabetes treatment regimens with 
guideline concordant adherence being associated with improved glycemic control, lower 
disease-related health-care expenditures, and reduced mortality.6,7 However, adherence 
estimates generally range between 36% and 93% of prescribed medication regimens for 
adherence to oral hypoglycemic agents, with a significant proportion of patients failing to 
meet recommended adherence targets.8
Cramer8 and others9-11 reviewed factors associated with adherence to diabetes medicines. 
Identified factors associated with adherence include age, ethnicity, depression, regimen 
complexity, dosing frequency of medications, adverse effects, medication costs, patient 
education and beliefs, and social support. However, these reviews have not specifically 
considered the issue of oral hypoglycemic agent adherence in primary care and have not 
examined factors associated with adherence in the context of an intervention. Education 
alone is insufficient to produce significant adherence behavior change.12 Interventions 
tailored to the individual focusing on multiple factors inhibiting adherence have been found 
to be more effective than interventions that are not individually-focused or focus on a single 
adherence barrier.13,14 Understanding which type 2 diabetes patients are at greatest risk for 
nonadherence and subsequently poor clinical outcomes based on clinically identifiable 
patient characteristics would help to identify patients who might benefit from interventions 
in real world clinical settings.
Investigations attempting to examine individuals at risk for poor adherence share one major 
shortcoming, they treat adherence as a discrete outcome despite the varying nature of 
adherence over time. Adherence to oral hypoglycemic agents has been assessed through 
proportions at singular point(s) in time with little evaluation of variation over time and 
group classification. We used an innovative technique for longitudinal data analysis, the 
general growth curve mixture model (GGCMM), in order to study individual differences in 
adherence and change over time. This technique identifies different subgroups of patients 
based on their underlying trends and allows for the examination of membership in the 
subgroups in relation to baseline patient characteristics and subsequent clinical outcomes. 
Prior work examining adherence to oral hypoglycemic agents has also been limited by 
recruitment from insurance entities, subjective adherence assessments, and/or primarily 
Caucasian samples (e.g.15-18). We used an objective assessment of adherence, electronic 
monitoring data, and our sample is drawn from primary care practices serving 
socioeconomically and ethnically diverse patients.
Our investigation used longitudinal adherence patterns to identify subgroups of type 2 
diabetes patients at risk for nonadherence and poor glycemic control at 12 weeks. Our 
purpose was to further understand (1) the course of oral hypoglycemic agent adherence 
patterns over 12 weeks among type 2 diabetes patients in primary care, (2) whether such 
patterns are related to patient characteristics; and, (3) whether patterns predict glycemic 
control at 12 weeks (Figure 1). We employed data from a primary care randomized 
de Vries McClintock et al. Page 2
Behav Med. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
controlled trial in which the study intervention was implemented at the patient level and 
involved an integrated care specialist working with physicians to provide care.19 We 
hypothesized that type 2 diabetes patients would have distinct patterns of adherence over the 
12 week period. We hypothesized based on the literature that patients who were younger, 
male, non-white, depressed, on a dosing frequency greater than 1 per day, or had a greater 
medical burden would be more likely than others to have a pattern of nonadherence.15,20-23 
In addition, we hypothesized that patients in usual care would be less likely to adhere than 
patients in the intervention condition. Finally, we hypothesized that patients who were 
adherent or had increasing adherence across 12 weeks would be more likely to have 
Hemoglobin A1c (HbA1c) in comparison with patients who were nonadherent. Identifying 
patterns of adherence to oral hypoglycemic agents over 12 weeks linked to the outcome of 
glycemic control at 12 weeks will set the stage for interventions targeting resources for 
persons most at risk for nonadherence.
To our knowledge, no study has examined patient characteristics, pattern of time-varying 
adherence, and outcome in a primary care trial of diabetes management among type 2 
diabetes with the ultimate goal of translating the knowledge into improving clinical 
outcomes. The Global Burden of Disease Study 2010 and the World Health Organization 
(WHO) list diabetes as a leading cause of disability.24 According to the WHO, the 
effectiveness of adherence interventions may have a far greater impact on the health of the 
population than any improvement in specific medical treatments.25 Identifying type 2 
diabetes patients at risk for poor adherence is key to identifying groups of patients at greatest 
need for intervention and follow-up.
Methods
Recruitment
A Brief Intervention to Improve Adherence through Integrated Management of type 2 
Diabetes Mellitus and Depression Treatment was a randomized controlled trial designed to 
assess whether an intervention in primary care improved glycemic control and depressive 
symptoms in type 2 diabetes patients. Patients were recruited from three primary care 
practices in Philadelphia, Pennsylvania. Patients were randomly assigned to the integrated 
care intervention or usual care. Electronic medical records were screened between April 
2010 to April 2011 for patients with a diagnosis of type 2 diabetes and a prescription for an 
oral hypoglycemic agent within the past year. The study is described in detail elsewhere.19
Study Design
The purpose of the 2-week run-in phase was to assess the feasibility of use of Medication 
Event Monitoring System (MEMS) caps and to allow for the collection of pre-intervention 
adherence rates. Data collected during this phase also included baseline demographics and 
glycated hemoglobin (HbA1c) assays to measure glycemic control. After the two-week run-
in phase, phase 2 of the study began in which patients were randomized to the integrated 
care intervention or usual care.
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Intervention and Usual Care
The integrated care manager worked individually with patients to address factors resulting in 
nonadherence including depression, chronic medical conditions, function, cognition, social 
support, cost of medications, side effects, and past experiences with medications. Through in 
person sessions and telephone conversations the integrated care manager provided education 
about depression and type 2 diabetes, emphasizing the importance of controlling depression 
to manage diabetes; help to identify target symptoms; explanations for the rationale for 
antidepressant and oral hypoglycemic agent use; assessment for side-effects and assistance 
in their management; assessment for progress (e.g. reduction in depressive symptoms and 
improvement in finger stick results); assistance with referrals; and monitoring and response 
to life-threatening symptoms (e.g. chest pain, suicidal thoughts and actions).
The intervention was presented to patients as a supplement to, rather than a replacement for, 
existing primary care treatment. Over a three month period patients had three 30 minute in-
person sessions (baseline, 6 weeks and 12 weeks) and two 15-minute telephone monitoring 
contacts. Usual care patients underwent in-person assessments at the same time points as the 
intervention. Research assistants conducted all assessments blinded to patient's 
randomization status.
Adherence to Oral Hypoglycemic Agents
Adherence to oral hypoglycemic agents was measured using electronic monitoring data 
obtained from the Medication Event Monitoring System (MEMS) Caps. MEMS caps on pill 
bottles record the precise date and time of container opening. Electronic drug monitoring 
data were assessed as the proportion of medication MEMS cap openings in a given week 
relative to the prescribed doses for the week. Our adherence calculation did not include 
excessive bottle openings or openings that exceeded the number of prescribed doses for the 
week.
Glycemic control
In accordance with American Diabetes Association Guidelines1 blood glycemic control was 
assessed at baseline and 12 weeks. The in2it A1C Analyzer provides point of care testing 
and was used to obtain Hemoglobin A1c (HbA1c) assays. This device has acceptable 
precision and agreement in comparison with laboratory services.26
Baseline Covariates
Standard questions were employed to obtain patient information on age, gender, ethnicity, 
marital status, and education. Consistent with prior investigations age was dichotomized as 
> 60 years and less than 60 years.27 Medical comorbidity was assessed by self-report at 
baseline. The Mini-Mental State Examination (MMSE) assessed cognitive status and has 
been widely employed for clinical and research purposes.28 The MMSE is a short 
standardized instrument that assesses orientation to time and place, registration, memory, 
attention and concentration, praxis, and constructional and language capacity.29 As in prior 
work, MMSE scores were analyzed as a dichotomous variable with a clinical threshold of 
27.30,31 Functional status was measured using the Medical Outcomes Study Short Form 
(SF-36).32 Depressive symptoms were assessed using the nine-item Patient Health 
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Questionnaire (PHQ-9). The PHQ-9 is a self-administered version of the PRIME-MD 
diagnostic instrument for mental disorders.33
Analytic strategy
In the first phase of this analysis, general growth curve mixture models (GGCMMs) were 
applied to indicators of adherence to oral hypoglycemic medication over the 12-week period 
to identify different adherence patterns.34 Binary indicators were adherence measurements 
assessed by MEMS caps at weekly intervals over a 12-week period. For each adherence 
assessment patients were categorized as adherent if they took at least 80% of their pills in 
the interval. Otherwise, patients were considered to be nonadherent. Greater or equal to 80% 
adherence was used because the 80% cut-point has been used as a standard to which other 
measures are compared.35 The model for the adherence patterns included random intercepts 
and slopes to account for within-subject correlations and separate fixed effect intercepts and 
fixed effects slopes for time within each latent class or pattern of adherence. We compared 
the results of this longitudinal linear model to models that accommodated nonlinear changes 
in adherence across time. The classifications into different patterns of adherence were 
similar across the different models, so we based our results on the simpler linear model. 
Number of classes was determined through examination of fit indices (AIC and BIC) as well 
as for clinically interpretable results. The Rubin-Lo-Mendell test was employed to determine 
if additional classes added further information to the model.36
In the second phase of this analysis, we examined differences in baseline patient 
characteristics across adherence profile types (adherent (n=67), increasing adherence (n=52), 
and nonadherence (n=61)) using χ2 for binary variables and analysis of variance (ANOVA) 
for continuous variables. We added patient characteristics and practice indicators to the 
GGCMM, one at a time to evaluate their association with class membership. Covariates that 
were significant at the p<0.10 level were included in the final model. Next, the relationship 
between the baseline covariates significant at the p<.10 level and latent classes or patterns of 
adherence was simultaneously assessed. The results were reported as odds ratios and 
corresponding confidence intervals. The baseline covariates were selected on the basis of 
previous literature on patient characteristics associated with adherence to oral hypoglycemic 
agents. We also examined interaction terms for which we had an a priori hypothesis: 
intervention by cognition and an intervention by education.
In the third phase, patients were classified into categories of longitudinal adherence profile 
types based on the largest posterior probability of membership in a certain class. Logistic 
regression related latent class variables to the clinical outcome of glycemic control at 12 
weeks. Glycemic control was examined both continuously and categorically. As 
recommended by clinical guidelines, the categorical outcome was assessed using a cutoff of 
HbA1c < 7% at 12 weeks.1 The results of the categorical outcome are presented in the form 
of odds ratios and 95% confidence intervals. Consistent with prior work, the model included 
terms to adjust for age, ethnicity, gender, marital status, educational attainment, functional 
status, frequency of medication administration, number of medications, number of medical 
conditions, cognitive status, intervention condition, pre-intervention adherence and baseline 
clinical outcome.37 We set α at 0.05, recognizing that tests of statistical significance are 
de Vries McClintock et al. Page 5
Behav Med. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
approximations that serve as aids to inference. The GGCMM was fitted using Mplus version 
7 (Muthén & Muthén)38 and other analyses were conducted in STATA version 12 for 
Windows (STATA Corporation, College Station, TX).
Results
Study sample
The CONSORT flow diagram for the Brief Intervention to Improve Adherence through 
Integrated Management of type 2 Diabetes Mellitus and Depression Treatment trial has been 
published elsewhere.19 The protocol was approved by the University of Pennsylvania 
Institutional Review Board. In brief, out of 715 patients identified by electronic medical 
records with type 2 diabetes, 265 were eligible and were approached for screening. Among 
type 2 diabetes patients who were approached, 190 were enrolled (71.7% participation rate). 
Patients who participated and patients who refused were similar in terms of key 
demographic characteristics such as age, gender, and ethnicity. After consent was obtained 
patients were assessed over a 2-week run-in phase in which medication adherence was 
examined. At the two-week visit, six patients had their medication discontinued, two 
patients were lost to follow-up and 182 patients were randomized to the integrated care 
intervention or usual care. In addition, two patients in the integrated care intervention were 
lost to follow-up subsequent to randomization. The remaining 180 patients completed all 
study visits.
The mean age of our sample was 57.4 years (standard deviation (s.d.) 9.5 years, range 32 to 
84 years), and 122 (67.8%) of the patients were women. The self-identified ethnicity of 
patients was 65 white (36.1%), 102 African-American (56.7%), 7 Hispanic (3.9%), and 6 
(3.3%) who self-identified as ‘other.’ In all, 69 persons (38.33%) were married, and 29 
persons (16.1%) had less than a high school education. The mean MMSE score was 28.2 
(s.d. 2.3). Baseline patient characteristics across adherence profile types (adherent (n=67), 
increasing adherence (n=52), and nonadherence (n=61)) are displayed in Table 1. White 
respondents and patients assigned to the intervention condition were more likely to show an 
adherent or increasing adherence pattern (p<.05). Physical functioning SF-36 score and 
mini-mental state examination (MMSE) scores significantly differed by adherence profile 
type (p<.05).
Patterns of adherence
Corresponding to the first phase of the analysis, we examined patterns of oral hypoglycemic 
agent adherence over 12 weeks. In order to delineate these patterns a series of GGCMMs 
were fitted to the MEMS data. The three-pattern model presented in Figure 2 improved the 
model fit over the two- and four-pattern models. The Rubin-Lo-Mendell test indicated that 
the three-pattern model of longitudinal adherence trajectories improved the model fit over 
the two-pattern model (p<0.001), with the four-pattern model providing no additional 
improvement in fit (p>0.99). Entropy, a measure of classification uncertainty, was 96.7% 
indicating a clear delineation of classes.
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Figure 2 shows the patterns of adherence represented by the categorical indicators of 
adherence at weekly intervals over the 12-week interval. The number of persons assigned to 
each pattern is presented at the bottom of Figure 2. Patients were assigned to each pattern 
according to their maximal posterior probabilities in each pattern. The first pattern (n= 67, 
37.0% of the entire sample, “adherent”) represents patients with a high probability of 
adherence at each time point. Patients with an “adherent” pattern had a probability of 
adherence at baseline of 72.1% and strongly increasing adherence over time (model slope: 
1.54 (95% confidence interval (CI): 0.90, 2.17)), with adherence reaching near 100% by the 
5th week.
The second pattern represents patients who have a low level of adherence at baseline and 
improve (“increasing adherence;” n = 52, 29.2% of the sample). Patients with “increasing 
adherence” had a modeled probability of adherence of 30.3% at baseline with a statistically 
significant increase in adherence over time (model slope of .22 (95% CI: 0.12, 0.32)). 
Modeled adherence reached over 80% by the end of the 12 week period. The third pattern 
(n=61, 33.8% of the entire sample, “nonadherent”) represents patients with a near zero 
probability of adherence at each time point. Patients with the nonadherent pattern had a near 
zero probability of adherence at baseline which remained near zero. To provide a more 
stable model, the slope parameters were fixed at zero for the third pattern of “nonadherent.”
Baseline Type 2 DM patient characteristics and patterns of adherence
Corresponding to the second phase of our analysis, we examined whether patient 
characteristics were associated with patterns of adherence to oral hypoglycemic agents. 
Odds ratios were employed to estimate the association of baseline patient characteristics 
with patterns of adherence. Two comparisons of patterns of adherence were examined: 
adherent vs. nonadherent and increasing adherence vs. nonadherent. Patients with MMSE 
score greater than or equal to 27 were more likely to have an adherent pattern compared to a 
nonadherent pattern (odds ratio (OR) = 1.29, 95% (CI) [1.06, 1.57]). Patients in the 
intervention condition were more likely to have an adherent pattern compared to a 
nonadherent pattern (OR = 11.6, 95% CI [4.08, 32.9]). In addition, patients in the 
intervention condition were more likely to have an increasing adherence pattern compared to 
a nonadherent pattern (OR= 41.31, 95% CI [13.87, 123.03]). In our final model, no 
associations between age, gender, ethnicity, education, depression status, dosing frequency, 
number of medications, functional status, or medical comorbidity and classes of adherence 
were found. We considered potential interaction terms: intervention by cognition and 
intervention by education, but none reached the level of significance of p < .05.
Clinical outcome of patterns of adherence: Hemoglobin A1c (HbA1c) at 12 weeks
Corresponding to the third phase of our analysis, we examined whether longitudinal profiles 
of adherence were associated with glycemic control as assessed by Hemoglobin A1c 
(HbA1c) at 12 weeks (Table 2). HbA1c at 12 weeks was strongly related to adherence 
patterns (χ2 (2)= 12.82, p<0.01). Patients with an increasing adherence pattern were 
significantly more likely to have an HbA1c < 7% (unadjusted OR = 4.39, 95% CI [1.91, 
10.12]); adjusted OR = 14.52, 95% CI [2.54, 82.99]) at 12 weeks in comparison with 
patients with the nonadherent pattern. Patients with an adherent pattern were not 
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significantly more likely to have an HbA1c < 7% (unadjusted OR = 1.86, 95% CI [0.92, 
3.76]; adjusted OR = 2.24, 95% CI [0.51, 9.92]) at 12 weeks in comparison with the 
nonadherent pattern. The model included terms to adjust for baseline differences in age, 
ethnicity, gender, marital status, educational attainment, functional status, frequency of 
medication administration, number of medications, number of medical conditions, cognitive 
status, primary care practice, baseline HbA1c, pre-intervention adherence and intervention 
condition.
Discussion
Examination of adherence over 12 weeks revealed three patterns: adherent, increasing 
adherence, and nonadherent. Patients who had a MMSE score greater than or equal to 27 
were more likely to have an adherent pattern than the nonadherent pattern compared to 
patients with a MMSE less than 27. Patients in the intervention condition were more likely 
to have an adherent pattern than a nonadherent pattern in comparison with patients in usual 
care. Similarly, patients in the intervention condition were more likely to have an increasing 
adherence pattern than a nonadherent pattern in comparison with patients in usual care. 
Patients with an increasing adherence pattern were also more likely to have an HbA1c < 7% 
at 12 weeks in comparison with patients with the nonadherent pattern. Our use of general 
growth curve mixture models allows us to assess distinct patterns of adherence over time 
instead of assessing adherence through proportions at singular point(s) in time with no 
assessment of variation over time. Our finding that patterns of adherence were differentially 
related to covariates of interest demonstrates the significance of delineating patterns of 
adherence over time.
Before discussing our findings, the results must first be considered in the context of some 
potential study limitations. First, we obtained our results from three primary care sites whose 
patients may not be representative of other primary care practices. However, the three 
practices were probably similar to other primary care practices in the region as they were 
diverse and varied in size. Second, there are limitations for all methods for assessing 
adherence. MEMS caps were our primary measure of adherence because as an objective 
measure of adherence they have a low failure rate and are more sensitive than other 
adherence measures.39 Any influence of MEMS caps on medication adherence would be 
experienced equally in both the intervention and usual care groups. Third, while research has 
assessed the 80% threshold for some medications,35 the clinical significance of this 
threshold has not been tested for many medications. Fourth, the length of follow-up for this 
trial was 12 weeks. However, significant intent-to-treat effects have been found in diabetes 
studies for a 12 week time period.14 Finally, even with confidence in our assessments of 
exposure, misspecification of the model relating adherence and blood glycemic control is 
still a possibility, such as when important variables have not been included in our model. We 
have tried to take care in adjusting our estimates of association for potentially influential 
characteristics that may relate to the outcome.
Despite these limitations, our results deserve attention because we attempted to characterize 
patterns of adherence over 12 weeks and the association of patient characteristics, 
intervention condition, and glycemic control with patterns of adherence. Assessment of a 
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single point in time is insufficient to understand variations in adherence over time. The three 
patterns of adherence we observed suggest a possible need for more intensive interventions 
targeting individuals, particularly those with MMSE less than 27. Our results suggest that 
the intervention condition increased the number of patients with an increasing adherence 
pattern that might have otherwise have had a nonadherent pattern.
Our results were not wholly consistent with our initial hypotheses. We did not find an 
association of age, sex, ethnicity, dosing frequency or medical burden with patterns of 
adherence. The lack of significant associations of age, sex, ethnicity, dosing frequency, 
depression status, or medical burden in patients suggests that the effects of these variables 
did not appear to influence patterns of adherence. In terms of depression status, the onset 
and nature of clinical diagnosis of depression as well the influence of these diagnoses on 
functioning may be more important in adherence than symptom presentation. In the 
examination of medical burden more careful assessment of the type of medical conditions 
and everyday related tasks that include medication-taking related items may be necessary to 
find a clear association with medical co-morbidity. Given a lack of identification of clear 
risk profiles for nonadherence, physicians may only be able to suspect nonadherence during 
the course of treatment for diabetes. If nonadherence is suspected, reasons for nonadherence 
should be examined and addressed to mitigate poor health prognoses and adverse clinical 
outcomes.37
Patients with MMSE greater than or equal to 27 were more likely to have an adherent than a 
nonadherent pattern. Past work has demonstrated that individuals with type 2 diabetes show 
accelerated cognitive decline, particularly in information-processing speed and executive 
function, compared with individuals without diabetes.40 While the association between 
cognition and diabetes is supported by a number of biologically plausible mechanisms, 
successful diabetes management is largely determined by self-care behaviors such as 
adherence. Lower cognitive functioning is associated with reduced health literacy41 and 
understanding of diabetes management,42 and greater dependency43 in persons with 
diabetes. Furthermore, lower cognitive functioning is also linked to increased risk of poor 
glycemic control,44 severe hypoglycemia,45 and mortality46 in patients with type 2 diabetes. 
Patients with lower cognition scores on the MMSE are at risk for a pattern of nonadherence 
and may need special attention for adherence management.
Our results suggest that the intervention increased the number of patients with an adherent 
and increasing adherence pattern that might have otherwise have had a nonadherent pattern. 
The strong association between intervention assignment and adherence pattern substantiates 
evidence that intervention strategies targeting multiple adherence barriers and which are 
tailored to the needs of each patient are successful in improving adherence.14 The 
interventionist worked individually with patients to address the factors involved in 
adherence that related to their specific characteristics and medical co-morbidity. The high 
recruitment rates and retention of minorities in this intervention has particularly significance 
given the disportionate burden of diabetes among minority groups.47 This is aligned with 
prior work demonstrating that integrated interventions are more engaging and acceptable to 
minorities than other intervention approaches.48-50 Furthermore, this intervention was both 
brief and simple in comparison with other diabetes interventions suggesting it may be a 
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sustainable strategy for improving patient adherence that can be implemented in primary 
care or other settings.51,52
Our findings hold particular clinical significance by demonstrating an increased likelihood 
of patients with HbA1c< 7% at 12 weeks among patients with an increasing adherence 
pattern. However, we did not find an association with the adherent pattern and glycemic 
control. As more is discovered regarding factors influencing adherence over time, we may 
be able to more accurately identify predictors of glycemic control. The lack of a significant 
association between the adherent pattern and glycemic control may be indicative of the 
severity of underlying disease or dosing inadequacy of oral hypoglycemic agents. Patients 
who are adherent to an inadequate dosage of oral hypoglycemic agents would be less likely 
to have glycemic control. In the future, longitudinal models may be used to link patient 
characteristics and patterns of adherence to the likelihood of adequate glycemic control in 
order to guide clinical treatment. Interventions tailored to the cognitive functioning of 
patients might have a substantial public health impact on glycemic control. A simple and 
brief adherence intervention was strongly related to adherence patterns and clinical outcome. 
Our results highlight the need for the development, implementation, and dissemination of 
clinical interventions to enhance medication adherence.
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Figure 1. 
Conceptual framework of baseline covariates, patterns of adherence, and glycemic control. 
Note: Patterns of adherence based on Medication Event Monitoring System (MEMS) data. 
Glycemic control at 12 weeks based on Hemoglobin A1c (HbA1c).
de Vries McClintock et al. Page 14
Behav Med. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
General growth curve mixture model analysis of adherence to oral hypoglycemic agents 
(number of patients in each class with plotted conditional probabilities) (n=180). Note: Data 
gathered from 2010-2011.
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Table 1
Baseline patient characteristics by adherence profile type (n=180)
Sociodemographic characteristics Adherent (n=67) Increasing Adherence (n=52) Non-adherent (n=61) P-value
Age, mean in years (s.d.) 56.7 (9.3) 59.3 (8.9) 56.7 (10.1) .25
White, n (%) 33 (49.3) 13 (25) 19 (31.2) .02
Gender, women n (%) 40 (59.7) 42 (80.8) 40 (65.6) .05
Married, n (%) 30 (44.8) 21 (40.4) 18 (29.5) .19
Less than HS education, n (%) 5 (7.5) 11 (21.2) 13 (21.3) .05
Functional status (SF-36)
Physical function score, mean (s.d.) 60.8 (30.1) 44.6 (32) 49.1 (32.6) .02
Medications
Frequency of oral hypoglycemic agent per day, 
mean (s.d.)
1.3 (.5) 1.3 (.6) 1.2 (.4) .77
Number of medications, mean (s.d.) 9.5 (4.5) 9.4 (4.4) 11 (5.4) .12
Health status
Medical conditions, mean (s.d.) 6.6 (2.5) 7.6 (3.4) 7.8 (3.7) .09
Cognitive status
MMSE, mean (s.d.) 28.8 (1.6) 28.1 (2.2) 27.6 (2.8) .01
Randomization assignment
Intervention, n (%) 40 (59.7) 44 (84.6) 8 (13.1) <.001
Depression status
PHQ-9, mean (s.d.) 9.5 (7.2) 11.5 (8.3) 10.1 (7.3) .35
Type 2 diabetes
HbA1c, mean (s.d.) 7.1 (1.7) 7.2 (1.9) 7.1 (2.0) .87
Abbreviations: s.d., standard deviation; HS, high school; SF-36, Medical Outcomes Study Short Form; MMSE, Mini-Mental State Examination; 
PHQ-9, nine-item Patient Health Questionnaire; Hb, hemoglobin. P-values represent comparisons according to χ2 for binary variables and analysis 
of variance (ANOVA) for continuous variables for categorical or continuous data, respectively.
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Table 2
Outcome glycemic control at 12 weeks for the three patterns of adherence (n=180)
HbA1c < 7% vs. HbA1c ≥ 7% at 12 weeks
Patterns of adherence (0-12 weeks) Unadjusted OR [95% CI] Adjusted OR** [95% CI]
Adherent (n=67) 1.86 [0.92, 3.76] 2.24 [0.51, 9.92]
Increasing adherence (n=52) 4.39* [1.91, 10.12] 14.52* [2.54, 82.99]
Non adherent (n=61) 1.00 1.00
Note: Hb = hemoglobin; OR = odds ratio; CI = confidence interval;
*p< .05
**
adjusted for age, ethnicity, gender, marital status, educational attainment, functional status, frequency of medication administration, number of 
medications, number of medical conditions, cognitive status, practice, baseline HbA1c, pre-intervention adherence and intervention condition.
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